Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05060991 · ClinicalTrials.gov registry record · Phase 4
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
A Phase 4 study of COVID-19 and Immunosuppression, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05060991 is a Phase 4 study of COVID-19 and Immunosuppression that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 50 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05060991, a Phase 4 study of COVID-19 and Immunosuppression, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Immunocompromised individuals, such as solid organ transplant (SOT) recipients are at high risk of COVID-19 associated complications and mortality. Retrospective studies so far have shown that a majority of SOT recipients did not develop appreciable anti-spike antibody response after a first, second, or even third dose of mRNA vaccine. Treatment with antimetabolites was associated with poor vaccine response. The goal of this study is 1) examine whether transient immunosuppression reduction improves the immune response to a third dose of SARS-CoV-2 mRNA vaccine in kidney transplant recipients and 2) to assess the safety of immunosuppression reduction before and after third dose SARS-CoV-2 mRNA vaccination.
Conditions Studied
Interventions
- DRUG Reduction in antimetabolite immunosuppression
Study Locations (1)
California
- University of California, Davis - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-09-24 |
| Est. Completion | 2025-12-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05060991
The ClinicalTrials.gov registry entry for NCT05060991 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Reduction in antimetabolite immunosuppression is the first listed.
NCT05060991 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05060991 about?
NCT05060991 is a clinical study titled "Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients". Immunocompromised individuals, such as solid organ transplant (SOT) recipients are at high risk of COVID-19 associated complications and mortality. Retrospective studies so far have shown that a majority of SOT recipients did not develop appreciable anti-spike antibody response after a first, second...
What is the current status of trial NCT05060991?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2021-09-24. Estimated completion is 2025-12-24.
What conditions does trial NCT05060991 study?
This clinical trial studies the following conditions: COVID-19, Immunosuppression, Vaccine Response Impaired.
What interventions are being tested in trial NCT05060991?
The interventions under investigation include: Reduction in antimetabolite immunosuppression (DRUG).
Who is sponsoring clinical trial NCT05060991?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05060991 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
RECRUITING · Phase 4
-
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
COVID-19 Reactogenicity
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
ACTIVE NOT RECRUITING · Phase 4
-
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.